Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing

被引:1
|
作者
Salama, Engie [1 ]
Lam, Stepfanie [1 ]
Gonsalves, Wilson, I [2 ]
Tzachanis, Dimitrios [3 ]
Momper, Jeremiah D. [1 ]
Saunders, Ila M. [1 ]
机构
[1] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, 9500 Gilman Dr,MC 0657, La Jolla, CA 92093 USA
[2] Mayo Clin, Div Hematol, Rochester, MN USA
[3] Univ Calif San Diego Hlth, Moores Canc Ctr, La Jolla, CA USA
关键词
multiple myeloma; pharmacokinetics; lenalidomide; renal impairment; CREATININE CLEARANCE; PHARMACOKINETICS; RECOMMENDATIONS;
D O I
10.1177/10600280221087218
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Lenalidomide is an immunomodulatory drug used to treat multiple myeloma that requires renal dosing adjustment based on Cockcroft-Gault (CG). Various equations to estimate kidney function exist and pose a potential issue with lenalidomide dosing. Objective The objective of this analysis was to evaluate the impact of estimating kidney function in newly diagnosed multiple myeloma patients with CG, Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and their potential impact on lenalidomide dosing. Methods Data from 1121 multiple myeloma patients at the time of diagnosis acquired from the Mayo Clinic were used to calculate creatinine clearance (CrCl) using Cockcroft-Gault with actual body weight (CG(ABW)), ideal body weight (CG(IBW)), or adjusted body weight (CG(AdjBW)); MDRD; and CKD-EPI for each subject. Discordances in dosing were then analyzed, and lenalidomide exposure was calculated for each subject to assess impact on pharmacokinetics of lenalidomide for patients who received discordant doses. Results Overall, approximately 16% of patients received a discordant dose when using MDRD or CKD-EPI instead of CG(ABW). The most common dose discordance was the decrease of a full dose of lenalidomide 25 mg when using CG(ABW) down to 10 mg and when using MDRD or CKD-EPI with 53.8% to 55.6% of all discordances in this category. When assessing different body weights, the most common discordance was a decrease from 25 to 10 mg when using CG(IBW) instead of CG(ABW); the same trend was observed when using CG(AdjBW) instead as well. Patients were also at risk of over- or underexposure based on area under the concentration versus time curve (AUC) for discordant dosing. Conclusion and Relevance A significant proportion of patients are at risk of under- or overdose of lenalidomide if CKD-EPI or MDRD are used instead of CG(ABW). Physicians should use CG(ABW) when estimating renal function to dose lenalidomide.
引用
收藏
页码:29 / 35
页数:7
相关论文
共 50 条
  • [41] Lenalidomide for Multiple Myeloma REPLY
    Palumbo, Antonio
    Rocci, Alberto
    Ludwig, Heinz
    Dimopoulos, Meletios A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (06): : 573 - 574
  • [42] Lenalidomide combination in multiple myeloma
    Pandey, Kaushal Raj
    LANCET ONCOLOGY, 2008, 9 (01): : 17 - 17
  • [43] Thalidomide and lenalidomide in multiple myeloma
    Mazumder, Amitabha
    Jagannath, Sundar
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (04) : 769 - 780
  • [44] Lenalidomide maintenance for multiple myeloma
    Brower, Vicki
    LANCET ONCOLOGY, 2012, 13 (06): : E238 - E238
  • [45] Lenalidomide in the treatment of multiple myeloma
    Rao, Kamakshi V.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (17) : 1799 - 1807
  • [46] Nursing Implications for Patients with Relapsed and/or Refractory Multiple Myeloma Receiving Combination Therapy with Daratumumab (Darzalex™) and Lenalidomide
    Catamero, Donna
    Spencer, Patrick
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E159 - E160
  • [47] LIVER INJURY IN 830 MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE
    Masood, Mohammed Umair
    Grinspan, Lauren
    Grewal, Priya
    Ahmad, Jawad
    Fabro, Roger Esteban
    Parekh, Samir
    Odin, Joseph
    HEPATOLOGY, 2021, 74 : 728A - 728A
  • [48] Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review
    Al-Ani, Fatimah
    Bastida Bermejo, Jose Maria
    Mateos, Maria-Victoria
    Louzada, Martha
    THROMBOSIS RESEARCH, 2016, 141 : 84 - 90
  • [49] Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide
    Atsushi Isoda
    Naru Sato
    Yuri Miyazawa
    Yoshinobu Matsumoto
    Mina Koumoto
    Masahito Ookawa
    Morio Sawamura
    Morio Matsumoto
    International Journal of Hematology, 2015, 102 : 271 - 277
  • [50] Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
    Gao Tiantao
    Liu Xinghong
    Shen Qi
    Luo Zhu
    Feng Ping
    Miao Jia
    Zheng Li
    Chen Donglin
    Xiang Jin
    中华医学杂志英文版, 2022, 135 (02) : 250 - 252